pharma · Critical Limb Ischemia (CLI) · Sarcoma · DSGN
Lxo Ireland Designated
Lxo Ireland Designated Activity Company
Lxo Ireland Designated is a pharma organization headquartered in CARLSBAD, CA, IE. It trades on NYSE under ticker DSGN. Primary therapeutic focus areas include Critical Limb Ischemia (CLI), Sarcoma, Friedreich Ataxia, HP
Company details
- Status
- Public
- HQ
- CARLSBAD, CA, IE
- Programs
- 68
- Drugs
- 61
- Patents
- 201
Quick answer
Lxo Ireland Designated is a pharma organization headquartered in CARLSBAD, CA, IE. It trades on NYSE under ticker DSGN. Primary therapeutic focus areas include Critical Limb Ischemia (CLI), Sarcoma, Friedreich Ataxia, HPV Infection, Prostate Cancer. NovaPharmaNews links 68 clinical program(s), 1 drug profile(s), and 201 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (30), phase 3 (17), phase 1 (16).
Company snapshot
Lxo Ireland Designated maintains 68 tracked programs across Critical Limb Ischemia (CLI), Sarcoma, Friedreich Ataxia, HPV Infection, Prostate Cancer, Acute Graft Versus Host Disease, ALK-Positive Non-Small Cell Lung Cancer (NSCLC), Transplant-Related Hematologic Malignancy, Sars-CoV2, Osteoarthritis, Knee, Severe Trophic Corneal Ulcers Refractory to Conventional Treatment, Peripheral Vascular Dise
- 1 approved product(s) across US/EU regulatory metadata.
- 68 active pipeline program(s) linked via ClinicalTrials.gov.
- 201 US patent(s) indexed to this assignee profile.
Public regulatory, clinical, patent, and corporate records for Lxo Ireland Designated. Not investment advice.
Catalysts
Upcoming readouts, regulatory dates, and congress activity.
- approval
Friedreich's Ataxia and Obesity Treatment Updates: Design Therapeutics and Vincentage Insights
- trial_data
Design Therapeutics' Friedreich's Ataxia Data and Vincentage's Obesity Results: A Strategic Analysis
Recent coverage
Friedreich's Ataxia and Obesity Treatment Updates: Design Therapeutics and Vincentage Insights
Design Therapeutics presents new data for its Friedreich's Ataxia (FA) therapy, potentially advancing the treatment landscape for this rare neurological disorder. Concurrently, Vincentage reports significant obesity treatment outcomes from China, signaling shifts in the weight management market.
Design Therapeutics' Friedreich's Ataxia Data and Vincentage's Obesity Results: A Strategic Analysis
Design Therapeutics presents new data on its Friedreich's Ataxia program, while Vincentage reports significant obesity treatment outcomes from China. These developments offer critical insights for pharmaceutical BD, strategy, and investment teams.
Top assets
Lead pipeline drugs
- Marketed / approved
- Marketed / approved
- Marketed / approved
- Marketed / approved
Active clinical programs
- Phase 3
- Phase 3
- Phase 3
- Phase 3
Momentum
Proprietary activity score for Lxo Ireland Designated.
2 active signals
Signal breakdown
- Clinical trials
- Nova articles
- Patents filed
- FDA actions
- SEC filings
- Conference presentations
- Pipeline advances
Competitor landscape
Therapeutic-area overlap peers from registry and pipeline signals.
- Peer + 0 momentum
Recent activity
Latest pipeline, patent, and corporate events for Lxo Ireland Designated.
- Clinical update
- Clinical update
- Clinical update
- Clinical update
- Clinical update
Quick answers
Common questions about this sponsor — for analysts and search.
-
What is Lxo Ireland Designated?
-
Is Lxo Ireland Designated publicly traded?
-
What drugs does Lxo Ireland Designated develop or market?
-
What are the latest developments for Lxo Ireland Designated?
-
What therapeutic areas does Lxo Ireland Designated focus on?
Therapeutic focus
Therapeutic area distribution
Pipeline concentration by therapeutic area from linked clinical programs.